- Home
- URG vs RGNX Comparison
URG vs RGNX Comparison
Compare URG & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URG
- RGNX
- Stock Information
- Founded
- URG 2004
- RGNX 2008
- Country
- URG United States
- RGNX United States
- Employees
- URG N/A
- RGNX N/A
- Industry
- URG Precious Metals
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- URG Basic Materials
- RGNX Health Care
- Exchange
- URG Nasdaq
- RGNX Nasdaq
- Market Cap
- URG 394.0M
- RGNX 387.0M
- IPO Year
- URG N/A
- RGNX 2015
- Fundamental
- Price
- URG $1.09
- RGNX $8.74
- Analyst Decision
- URG Strong Buy
- RGNX Strong Buy
- Analyst Count
- URG 2
- RGNX 8
- Target Price
- URG $2.45
- RGNX $31.75
- AVG Volume (30 Days)
- URG 9.9M
- RGNX 1.0M
- Earning Date
- URG 08-08-2025
- RGNX 07-31-2025
- Dividend Yield
- URG N/A
- RGNX N/A
- EPS Growth
- URG N/A
- RGNX N/A
- EPS
- URG N/A
- RGNX N/A
- Revenue
- URG $33,706,000.00
- RGNX $156,718,000.00
- Revenue This Year
- URG N/A
- RGNX $327.08
- Revenue Next Year
- URG $251.38
- RGNX N/A
- P/E Ratio
- URG N/A
- RGNX N/A
- Revenue Growth
- URG 200.09
- RGNX 80.70
- 52 Week Low
- URG $0.55
- RGNX $5.04
- 52 Week High
- URG $1.53
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- URG 61.98
- RGNX 49.53
- Support Level
- URG $1.00
- RGNX $7.91
- Resistance Level
- URG $1.11
- RGNX $8.99
- Average True Range (ATR)
- URG 0.07
- RGNX 0.65
- MACD
- URG -0.00
- RGNX -0.05
- Stochastic Oscillator
- URG 79.17
- RGNX 37.70
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.